Venetoclax plus decitabine for relapsed or refractory T-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 19 and 79 years old.
- Your T-cell acute lymphoblastic leukemia (leukemia or lymphoma) has come back after treatment or never fully went away.
- You haven't had chemotherapy or another experimental drug within the last 2 weeks.
- Your kidneys and liver need to work well enough, based on blood tests (kidney function score of 30 or higher, bilirubin 3.0 or lower, liver enzymes less than 5 times the upper limit of normal).
- You cannot be pregnant or breastfeeding, and must agree to use birth control during treatment and for 3 months after.
- You cannot have active leukemia in your brain or spinal fluid, uncontrolled infections, or other cancers that need treatment right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
Hear when a new T Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.